ストックスクリーナーアプリを入手
50.61
1.36%
-0.7259
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
Can Supernus Pharmaceuticals Inc. stock sustain institutional interestJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Is Supernus Pharmaceuticals (SUPN) Offering Value After Strong Multi Year Share Price Gains - Sahm
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Lupin launches epilepsy drug in US - ET Pharma
Lupin Launches Topiramate Extended-Release Capsules in the United States - The Malaysian Reserve
(SUPN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Strong results lifted Supernus Pharmaceuticals (SUPN) in Q3 - MSN
India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR - marketscreener.com
Patterns Watch: Should I trade or invest in Supernus Pharmaceuticals Inc2025 Key Highlights & Reliable Price Action Trade Plans - baoquankhu1.vn
SupernusOutlook For 2026 Positive, Upholding Buy Rating (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Buy" at Wall Street Zen - MarketBeat
Published on: 2026-01-31 06:25:45 - baoquankhu1.vn
Supernus Pharmaceuticals amends merger agreement to adjust milestone payments - Investing.com
Supernus Revises Merger Milestone Payment Obligations Agreement - TipRanks
Is Supernus Pharmaceuticals Inc. being accumulated by smart moneyJuly 2025 Patterns & Fast Exit and Entry Trade Guides - mfd.ru
Published on: 2026-01-28 12:01:32 - baoquankhu1.vn
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Exploring a 24.76% Potential Upside - DirectorsTalk Interviews
Analysis Recap: Should you avoid Supernus Pharmaceuticals Inc. stock right nowWeekly Trade Analysis & Risk Managed Trade Strategies - baoquankhu1.vn
Price-Driven Insight from (SUPN) for Rule-Based Strategy - Stock Traders Daily
Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders, they're still up 64% over 5 years - simplywall.st
Loss Report: Is Supernus Pharmaceuticals Inc stock forming a triangle pattern2025 Buyback Activity & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Supernus Pharmaceuticals (SUPN) Stock Analysis: Exploring A 22.67% Potential Upside - DirectorsTalk Interviews
Chart Watch: Is Supernus Pharmaceuticals Inc a stock for growth or value investorsRate Cut & Weekly Sector Rotation Insights - baoquankhu1.vn
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Investment Review: Should you avoid Supernus Pharmaceuticals Inc stock right now2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
(SUPN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - MSN
How Supernus Pharmaceuticals Inc. stock performs after earningsJuly 2025 Pullbacks & Comprehensive Market Scan Insights - Улправда
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cantor Fitzgerald reiterates Overweight rating on Supernus Pharmaceuticals stock By Investing.com - Investing.com UK
Will Supernus Pharmaceuticals Inc. stock deliver long term returnsEarnings Performance Report & Verified Swing Trading Watchlist - Улправда
Why retail investors pile into Supernus Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Investment Recap: How Supernus Pharmaceuticals Inc stock compares to growth peersProduct Launch & Weekly High Momentum Picks - Bộ Nội Vụ
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Unlocking a 24% Potential Upside in the CNS Market - DirectorsTalk Interviews
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
(SUPN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Supernus Pharmaceuticals Earnings Notes - Trefis
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Rice Hall James & Associates LLC Has $22.75 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
SUPN (Supernus Pharmaceuticals) EV-to-OCF : 37.98 (As of Dec. 25, 2025) - GuruFocus
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) SVP Sells 20,000 Shares of Stock - MarketBeat
Supernus Pharmaceuticals Senior VP Sells Shares - TradingView — Track All Markets
Supernus Pharmaceuticals (SUPN) Is Up 6.0% After FDA Approval Of ONAPGO Parkinson’s DrugHas The Bull Case Changed? - Sahm
Optimism flows from pot to psychedelics: Atai Beckley, Supernus stocks rise after analyst flags positive tailwinds from Trump’s marijuana order - MSN
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order - Stocktwits
Stifel raises Supernus Pharmaceuticals stock price target to $55 from $50 - Investing.com Canada
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 - Finviz
0.00%
9.53%
大文字化:
|
ボリューム (24 時間):